Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ferring Pharmaceuticals

< Previous 1 2 Next >
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
From Ferring Pharmaceuticals
Via Business Wire
Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal microbiota, live – jslm)
From Ferring Pharmaceuticals
Via Business Wire
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
From Ferring Pharmaceuticals
Via Business Wire
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
From Ferring Pharmaceuticals
Via Business Wire
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
From Ferring Pharmaceuticals
Via Business Wire
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
From Ferring Pharmaceuticals
Via Business Wire
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts
From Ferring Pharmaceuticals
Via Business Wire
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
From Ferring Pharmaceuticals
Via Business Wire
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
From Ferring Pharmaceuticals
Via Business Wire
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
From Ferring Pharmaceuticals
Via Business Wire
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Tickers RPRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.